Overexpression of p53 protein associates decreased response to chemoradiotherapy in patients with esophageal carcinoma

Modern Pathology

Volumn 12, Issue 3, 1999, Pages 251-256

  Yang, Bin ^a   Rice, Thomas W ^a   Adelstein, David J ^a   Rybicki, Lisa A ^a   Goldblum, John R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Adenocarcinoma; Chemoradiotherapy; Esophagus; Immunohistochemistry; P53; Squamous cell carcinoma

Indexed keywords

CISPLATIN; FLUOROURACIL; PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; BIOPSY; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DRUG THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOTHERAPY; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033014768     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hoff SJ, Stewart JR, Sawyers JL, Murray MJ, Merrill NH, Adkins RB, et al. Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma. Ann Thorac Surg 1993;56:282-6.
2. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335:462-7.
3. Forastiere AA, Orringer MB, Perez-Tamayo C, Urba SG, Zahurak M. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol 1993;11:1118-23.
4. Adelstein DJ, Rice TW, Becker M, van Kirk MA, Kirby TJ, Koda A, et al. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal cancer. Cancer 1997;80:1011-20.
5. Rice TW, Boyce GA, Sivak MV, Adelstein DJ, Kirby TJ. Esophageal carcinoma: esophageal ultrasound assessment of pre-operative chemotherapy. Ann Thorac Surg 1992;53:972-7.
6. Bennett WP, Hollstein MC, He A, Zhu SM, Resau JH, Trump BF, et al. Archival analysis of p53 genetic and protein alterations in chimeric esophageal cancer. Oncogene 1991; 6:1779-84.
7. Sorbia M, Porschen R, Borchard F, Horstmann O, Willers R, Gabbert HE. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994;74: 2218-23.
8. Sasano H, Miyazaki S, Gooukon Y, Nichikira T, Sawai T, Nagura H. Expression of p53 in human esophageal carcinoma: an immunohistochemical study with correlation to proliferating cell nuclear antigen expression. Hum Pathol 1992;23:1238-43.
9. Ramel S, Reid BJ, Sanchez CA, Blount PL, Levine DS, Neshat K, et al. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology 1992;102:1220-8.
10. Carson AG, Mukhopadhyay T, Cleary KR, Ro JK, Levine B, Roth JA. p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res 1991;51:4495-9.
11. Hartwell L, Kastan M. Cell cycle control and cancer. Science 1994;266:1821-8.
12. Lowe SW, Ruley HE, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74:957-67.
13. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
14. Yang B, Eshleman JR, Berger NA, Markowitz SD. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 1996;2:1649-57.
15. Miyashita T, Hariga M, Hanada M, Reed J. Identification of a p53-dependent negative response elements in the bcl-2 gene. Cancer Res 1994;54:3131-5.
16. Miyashita T, Reed J. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80: 293-9.
17. Perego P, Giaola M, Righetti S, Supino R, Caserini C, Delia D, et al. Association between cisplatin resistance and mutation of p53 gene and reduced expression in ovarian carcinoma cell systems. Cancer Res 1996;56:556-62.
18. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, et al. Aberrant p53 expression predicts clinical response to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995;55:3038-42.
19. Righetti S, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi M, et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996;56:689-93.
20. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnson H, Varhaug JE, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-4.
21. Brett MC, Pickard M, Green B, Howel-Evans A, Smith D, Kinsella A, et al. p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur J Surg Oncol 1996;22:182-5.
22. Puglisi F, Di Loreto C, Avellini C, Fongione S, Cacitti V, Beltrami CA. Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the esophagus. J Clin Pathol 1996;49:456-9.
23. Lam K-Y, Law S, Ma LT, Ong SK, Wang J. Preoperative chemotherapy for squamous cell carcinoma of the esophagus: do histological assessment and p53 overexpression predict chemoresponsiveness? Eur J Cancer 1997;33:1221-5.
24. Hickey K, Grehan D, Reid IM, O'Briain S, Walsh TN, Hennessy PF. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer 1994;74:1693-8.
25. Baas IO, Mulder J-WR, Offerhaus JA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
26. Prives C, Manfredi JJ. The p53 tumor suppressor protein meeting review. Genes Dev 1993;7:529-34.
27. Peng H-Q, Hogg D, Malkin D, Bailey D, Gallie BL, Bulbul M, et al. Mutations of the p53 gene do not occur in testis cancer. Cancer Res 1993;53:3574-8.
28. Lutzker SG, Levine AJ. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat Med 1996;2:804-10.